Cymabay Therapeutics Inc (NASDAQ:CBAY)
| 4.02 Delayed Data As of Oct 21 |  +0.03 / +0.75%Today’s Change | 3.39 Today|||52-Week Range 9.06 | -29.97% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $271.9M |
Company Description
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products pipeline include Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Contact Information
CymaBay Therapeutics, Inc. 7575 Gateway Boulevard Newark California 94560 |
Employees
Shareholders
| Other institutional | 51.74% |
| Mutual fund holders | 18.29% |
| Individual stakeholders | 15.76% |
Top Executives
| Sujal Shah | President, Chief Executive Officer & Director |
| Daniel Menold | Vice President-Finance |
| Charles A. McWherter | Chief Scientific Officer & Senior Vice President |
| Dennis D. Kim | Chief Medical Officer |
| Paul T. Quinlan | Secretary & Chief Compliance Officer |
